Table 3: Statistical significant dates involving Hox polymorphisms.
Groups | Polymorphism | Nucleoside | MBS patients (n = 30) | Control groups (n = 30) | p-value |
MBS patients Versus Non-MBS patients | A315T (Hoxb1) | MBS patients (n = 30) | Non-MBS patients (n = 30) | ||
AA | 26 (86.7) | 17 (56.7) | 0.02 | ||
AT | 4 (13.3) | 12 (40) | |||
TT | 0 (0) | 1 (3.3) | |||
MBS patients Versus Non-consanguineous and Non-syndromic patients (control group 2) | C243T (Hoxb1) | MBS patients (n = 30) | Non-consanguineous and non- syndromic (n = 15) | p-value | |
CC | 22 (73.3) | 6 (40) | 0.03 | ||
CT | 8 (26.7) | 7 (46.7) | |||
TT | 0 (0) | 2 (13.3) | |||
A315T (Hoxb1) | AA | 26 (86.7) | 7 (46.6) | 0.01 | |
AT | 4 (13.3) | 7 (46.7) | |||
TT | 0 (0) | 1 (6.7) | |||
G456A (Hoxb1) | GG | 20 (66.7) | 5 (33.3) | 0.02 | |
GA | 10 (33.3) | 7 (46.7) | |||
AA | 0 (0) | 3 (20) | |||
MBS patients Versus Their relatives (Control group 1) | G218A (Hoxa1) | MBS patients (n = 30) | Consanguineous (n = 15) | p-value | |
GG | 0 (0) | 1 (6.6) | 0.03 | ||
GA | 11 (36.7) | 1 (6.7) | |||
AA | 19 (63.3) | 13 (86.7) |